Produção Nacional
Revisado por pares
Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
2011; Elsevier BV; Volume: 15; Issue: 4 Linguagem: Inglês
10.1016/s1413-8670(11)70208-2
ISSN1678-4391
AutoresLuís Jesuino De Oliveira Andrade, Ajax Mercês Atta, Maria Luiza Brito de Sousa Atta, Célia Neder Kalil Mangabeira, Raymundo Paraná,
Tópico(s)interferon and immune responses
ResumoTo investigate the frequency of thyroid disorders (TD) in patients with chronic hepatitis C before and during interferon-alpha (IFN-α) and ribavirin (RIB) treatment.Prospective study.We prospectively studied 65 anti-HCV and viral RNA positive patients. Free thyroxine, thyroid-stimulating hormone, and thyroid peroxidase antibodies (TPO-Ab) were systematically tested at entry (m0), week 12 (m3) and week 24 (m6) of treatment.Mean age of the 65 patients (38 females and 27 males) was 49.61 ± 11.83 years. Seven (10.76%) patients presented baseline thyroid disorders (m0), three had thyroid dysfunction, and four were TPO-Ab positive. Thyroid disorders occurred in the first 12 weeks of treatment in 11 (16.92%) patients, four with thyroid dysfunction, and seven with TPO-Ab positive (m3). A total of 18 patients (27.69%) developed TD after 24 weeks of treatment, 7 with thyroid dysfunction, and 11 with TPO-Ab positive (m6). The relative risk of developing hypothyroidism found in this study was 1.3 (95% CI: 1.1 to 1.6), hyperthyroidism 1.2 (95% CI: 1.1 to 1.4), and TPO-Ab positivity 7.6 (95% CI: 3.9 to 14.5). The study showed a significant association between female sex and thyroid disease (p = 0.009).Thyroid dysfunction and autoimmune TD were observed during IFN-α and RIB therapy.
Referência(s)